CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $85,719,562
- in 13 filings, $45.5M under 10b5-1 plans
Net −$85,719,562. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-17 | Sukhatme Mayukh President & CIO | Option exercise · Common Shares | −284,707 | 13,696,479 | ||
| 2026-08-14 | Sukhatme Mayukh President & CIO | Option exercise | +243,177 | $3.85 | $936K | 18,873,916 |
| 2026-08-14 | Sukhatme Mayukh President & CIO | Sale | −243,177 | $36.23 | $8.8M | 18,630,739 |
| 2026-08-14 | Sukhatme Mayukh President & CIO | Option exercise · Common Shares | −243,177 | 13,981,186 | ||
| 2026-07-27 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,813,063 |
| 2026-07-27 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $34.95 | $7.0M | 1,613,063 |
| 2026-07-27 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 4,044,834 | ||
| 2026-07-17 | MOMTAZEE JAMES C Director | Grant or award | +405 | 109,810 | ||
| 2026-07-17 | Epperly Melissa B, Director | Grant or award | +543 | 17,017 | ||
| 2026-07-17 | Oren Ilan Director | Grant or award | +775 | 121,004 | ||
| 2026-06-30 | Gline Matthew CEO | Shares withheld for taxes | −76,171 | $35.39 | $2.7M | 16,659,945 |
| 2026-06-30 | Torti Frank President and Vant Chair | Shares withheld for taxes | −40,310 | $35.39 | $1.4M | 13,536,202 |
| 2026-06-30 | Sukhatme Mayukh President & CIO | Shares withheld for taxes | −46,878 | $35.39 | $1.7M | 18,630,739 |
| 2026-06-30 | Fitzgerald Meghan Director | Option exercise 10b5-1 | +10,000 | $8.80 | $88K | 52,963 |
| 2026-06-30 | Fitzgerald Meghan Director | Sale 10b5-1 | −10,000 | $34.90 | $349K | 42,963 |
| 2026-06-30 | Fitzgerald Meghan Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 38,578 | ||
| 2026-06-30 | MANCHESTER KEITH S Director | Sale | −12,380 | $35.28 | $437K | 13,689,166 |
| 2026-06-30 | MANCHESTER KEITH S Director | Sale | −200,000 | $35.45 | $7.1M | 1,748,403 |
| 2026-06-30 | Gold Daniel Allen Director | Sale | −12,380 | $35.28 | $437K | 13,689,166 |
| 2026-06-30 | QVT Financial LP Director by Deputization | Sale | −12,380 | $35.28 | $437K | 13,689,166 |
Page 6 of 29 · 570 trades